𝗪𝗵𝗼 𝗶𝘀 𝘁𝗵𝗶𝘀 𝗲𝘃𝗲𝗻𝘁 𝗶𝗻𝘁𝗲𝗻𝗱𝗲𝗱 𝗳𝗼𝗿?
Limited Places
Discover more
This event is tailored for Genomic Laboratory Staff, including Professors, Researchers, Heads of Service, Clinical Scientists, Bioinformaticians, Lab Technicians, and more.
It also welcomes Genomic Purchasing Staff, such as buyers, commercial leads, procurement specialists, and distributors, to discuss the latest trends and solutions in genomic technologies.
Lastly, the event is ideal for Oncologists and Nursing Staff with an interest in genomics, providing a platform to explore the cutting-edge applications of genomics in oncology care.
| Event | Time | Details | Speaker |
|---|---|---|---|
| Delegate Arrival | 12:15 – 13:00 | Comfort break following travel, light refreshments provided. Tea and Coffee etc. | |
| Welcome | 13:00 – 14:15 | ‘Who is in the room’ – a high level view of the delegates from which countries they are from, professional backgrounds, etc | Jean-Pol Detiffe |
| Comprehensive Genomic Profiling (CGP) provides an insight into an individual’s cancer, so why is precision oncology still far from the reality for all patients? | 14:15 – 15:00 | Consider the ‘big picture’ challenges of implementing Comprehensive Genomic Profiling (CGP) and how these translate to local challenges that slow the pace of adoption of CGP in European laboratories. | Prof. Andrew Beggs |
| Documenting the value of CGP – a Belgium Society of Medical Oncologists (BSMO) study in collaboration with Belgian NGS Laboratories (The BALLETT Study) | 15:00 – 15:45 | The BALLETT Study aimed to evaluate the real relevance of CGP in routine usage and evidence that it could be achieved via a decentralized approach using products such as the OncoDEEP Kit. | Dr. Brigitte Maes |
| Comprehensive Genomic Profiling – What’s the Business Case? | 15:45 – 16:30 | In a constantly evolving marketplace with a range of CGP kit options available, laboratory leaders need help to switch and replace small ‘hot spot’ panels with a CGP solution. The question is how best can an assay be selected and what are the key metrics needed to support a business case? | Dr. Marcel Trautmann |
| Break out groups x2 – Tea and Coffee available throughout the afternoon (Delegates choose to attend 1 ahead of the day) | 16:30 – 17:30 | Delegates move to the breakout group which they signed up for and collect tea/coffee etc/comfort break | |
| Breakout group one – The impact of CGP on a patient’s journey, the treating oncologist’s view of using CGP, making use of the report and the challenges raised in the clinical setting | 17:00 – 17:40 | Hear of the impact of CGP on a single patient’s journey and debate the clinical challenges for the treating oncologist wishing to deliver on the promise of precision oncology for their patients | Patient Film/Dr. Cheng Boon |
| Breakout group two – A ‘deep dive’ into the OncoDEEP Kit and its application for CGP and specific biomarkers such as HRD | 17:00 – 17:40 | Hear why and how the OncoDEEP kit has been developed and what informed its design. Learn about key findings from OncoDNA’s own evolution and from the first OncoDEEP kit customers. | OncoDNA team |
| Closing remarks | 17:45 – 18:00 | Review of key points from Day One and how this leads into Day Two | Jean-Pol Detiffe |
| Drinks Reception and Dinner | 18:00 – 21:00 | A networking session followed by an exclusive dinner at the prestigious Max Raye Room. During the evening, Dr. Philip Beer will be presenting “The Role of Partnerships: Setting Up Clinical Reference Centres for Genomics.” He will reflect on what works well—and what doesn’t—in these collaborations, providing evidence of how successful partnerships can influence genomics policy over time.” |
| Event | Time | Details | Speaker |
|---|---|---|---|
| Delegate Arrival | 08:45 – 09:15 | Delegates sign up to a timeslot in the CGP clinic (1:1) to be held during the lunch period. This is an opportunity for delegates to review their needs as documented in their questionnaire which they will complete during the morning of Day 2. | |
| Welcome and how not to ‘rework the wheel’ when implementing CGP in your laboratory | 09:15 – 09:45 | Hear from a panel made up of existing OncoDEEP kit users as to what they would do differently if implementing the OncoDEEP kit again. | A panel from the SW London Genomic Laboratory Hub |
| Optimising your NGS workflow and supporting your laboratory workforce in the transition to the OncoDEEP kit | 09:45 – 10:15 | Learn how OncoDNA Field Application Specialist and Account Managers co-design plans with customers to ensure local laboratories optimise capacity to meet the increasing demand for CGP testing. | OncoDNA team |
| Coffee Break and action planning | 10:15 – 10:45 | Reflect on learnings from Day one and the morning of Day two. | Delegates |
| Flexible and Innovative – Delivering on the bigger picture | 10:45 – 12:00 | Learn how it’s not only OncoDEEP kits that can help create an economically viable, fully optimised, high throughput CGP service in your laboratory. | Delegates /OncoDNA team |
| Lunch, Networking and your 1:1 appointment at the CGP clinic | 12:00 – 14:00 | Scientific and Field Application Specialists, Scientific and Technology representatives (as appropriate) review the delegates’ questionnaire with them in the 1:1, providing guidance and support to address the individual’s needs when mobilising CGP testing in their laboratory using the OncoDEEP kit. | Delegates / OncoDNA team |
| Conference Summary and closing remarks | 14:00 – 15:00 | Conference Wrap Up and delegate feedback. | Jean-Pol Detiffe |
Dr. Brigitte Maes is a distinguished oncologist and researcher with a strong background in medical oncology. She is renowned for her contributions to precision medicine, particularly in the field of comprehensive genomic profiling (CGP). Dr. Maes has played a pivotal role in advancing personalized cancer treatments through her research, which focuses on the practical implementation and clinical benefits of CGP in routine oncology practice. Her work with the Belgium Society of Medical Oncologists (BSMO) and collaborations with various laboratories highlight her dedication to improving patient outcomes by leveraging cutting-edge genomic technologies.
Dr. Marcel Trautmann is a highly regarded expert in the field of molecular diagnostics and precision oncology. With a robust background in medical research and clinical applications, he has made significant contributions to the integration of advanced genomic technologies into clinical practice. Dr. Trautmann is particularly noted for his work on optimizing next-generation sequencing (NGS) workflows and developing business cases for the adoption of comprehensive genomic profiling (CGP) in laboratories. Dr. Trautmann’s expertise, coupled with his dedication to advancing precision medicine.
Dr. Katya Mokretar is a Clinical Scientist specializing in molecular oncology, with expertise in leukemia diagnostics and measurable residual disease (MRD) monitoring. Currently serving as Deputy Operations Lead in the Molecular Oncology Unit at Guy’s Hospital, she has extensive experience in next-generation sequencing (NGS) assays for diagnosing hematological malignancies. Her career spans roles in leading cancer genetics departments, where she has advanced genomic diagnostic tools for both leukemia and solid tumors. Dr. Mokretar is a member of prominent scientific organizations, including the European Haematology Association and British Society of Genetic Medicine (Synnovis)
Lucas Pavlou is a dedicated professional in the field of molecular diagnostics, with a focus on advancing genomic technologies for clinical applications. With a background in molecular biology and experience in comprehensive genomic profiling (CGP), Lucas has contributed to the implementation of cutting-edge diagnostic tools in lab practices. He is passionate about enhancing patient outcomes through precision medicine and the integration of next-generation sequencing technologies in routine healthcare settings.
Nicola Foot is a dedicated professional in the field of genomics, with expertise in developing innovative strategies for genomic technologies. With experience at the intersection of science and business, Nicola has a proven track record in driving projects from concept to implementation, fostering collaboration across teams, and advancing cutting-edge solutions in the genomics space. Passionate about translating scientific knowledge into real-world applications, Nicola is committed to pushing the boundaries of personalized healthcare and research.
Philip joined Step Pharma in June 2021 and was promoted from Vice President, Head of Research & Translation Medicine to Chief Scientific Officer in January 2021. Prior to this, he held senior leadership roles in biotech and biopharma companies, overseeing oncology drug development and biomarker discovery programmes. He is a cofounder of Gabriel Precision Oncology, a clinical software company also focused on improving outcomes for those living with cancer. Philip is a board-certified haematologist with over 16 years of frontline healthcare experience as well as biopharmaceutical industry experience, particularly in translational medicine, drug development, and biomarker discovery.
Philip is a Member of the Royal College of Physicians, UK, and a Fellow of the Royal College of Pathologists, UK. He holds a PhD in molecular cancer biology from the University of Cambridge, UK. Following this he conducted post-doctoral research studies at the BC Cancer Agency, Vancouver, Canada, and has more than 100 peer-reviewed publications. Philip is an Honorary Professor of Translational Medical at the Hull York Medical School, UK.
Dr. Cheng Boon is a highly skilled Consultant Oncologist with extensive experience in the field of oncology. Currently, Dr. Boon serves as a Consultant Oncologist at the University Hospitals of Derby and Burton NHS Foundation Trust, where he has been a key part of the team since June 2023. His role here involves providing expert care to cancer patients, collaborating with multidisciplinary teams, and advancing treatment protocols.
In addition to his position at Derby and Burton, Dr. Boon also holds a full-time consultant role at The Royal Wolverhampton NHS Trust. His work at this esteemed institution further demonstrates his commitment to delivering exceptional care and contributing to the advancement of oncological practices.
With a strong scientific background, he has founded several companies focused on life sciences and health technologies. His career is marked by a deep commitment to innovation, particularly in developing cutting-edge diagnostic tools and solutions that enhance healthcare outcomes. Detiffe is known for his leadership and ability to bridge the gap between scientific research and practical applications in the industry.
Sébastien Sauvage is a dedicated professional at OncoDNA, specializing in the integration of genomic data and personalized cancer care solutions. With a background in engineering and biotechnology, Sébastien plays a pivotal role in developing cutting-edge diagnostic tools that empower oncologists to make informed treatment decisions. His expertise in project management, data analysis, and innovative healthcare solutions helps drive advancements in precision oncology, ultimately improving patient outcomes.
1 Wimpole St, London W1G 0AE, United Kingdomine
Seats are limited for the OncoDEEP Kit European user meeting.
Secure your spot by clicking the button below.
Company
OncoDNA S.A. (headquarters)
Rue Louis Breguet 1
BE-6041 Gosselies
Links
Support
